GBT is a biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. The company has one FDA-approved therapy for sickle cell disease and one investigational therapy in development for the disease.

Recent News

02/20/20GBT Accepting Proposals for 2020 ACCEL Grants to Support Novel Access-to-Care Programs for People Living with Sickle Cell Disease
02/19/20GBT to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020
02/03/20GBT Announces New Employment Inducement Grants
01/08/20GBT Announces New Employment Inducement Grants

More »

Media Resources

Media Contact

Steven Immergut (media)